Publication Date
8-4-2023
Journal
NPJ Vaccines
DOI
10.1038/s41541-023-00706-x
PMID
37542081
PMCID
PMC10403580
PubMedCentral® Posted Date
8-4-2023
PubMedCentral® Full Text Version
Post-Print
Published Open-Access
yes
Keywords
Renal cell carcinoma, Preclinical research, DNA vaccines
Abstract
Immune-based checkpoint therapy has made significant progress in cancer treatment, but its therapeutic effect is limited. A replication-defective adenovirus (Ad) vaccine encoding tumor antigen carbonic anhydrase IX (CAIX) combined with Ad-encoding immune checkpoint PD-L1 was developed to treat renal carcinoma. Three tumor models, subcutaneous, lung metastasis and orthotopic tumor were established, and Ad vaccines were used to immunize them and evaluate the vaccine's therapeutic effect. Compared to the single Ad vaccine group, the subcutaneous tumor growth was significantly reduced in Ad-CAIX/Ad-PD-L1 combination group. Co-immunization of Ad-CAIX/Ad-PD-L1 enhanced the induction and maturation of CD11c
Comments
Associated Data